Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Endometrial carcinoma: Clinical features and diagnosis

Lee-may Chen, MD
Jonathan S Berek, MD, MMS
Section Editors
Barbara Goff, MD
Don S Dizon, MD, FACP
Deputy Editor
Sandy J Falk, MD, FACOG


Uterine cancer is the most common gynecologic malignancy in developed countries and is the second most common in developing countries (cervical cancer is more common). Adenocarcinoma of the endometrium (lining of the uterus) is the most common histologic site and type of uterine cancer. (See "Endometrial carcinoma: Epidemiology and risk factors".)

Abnormal uterine bleeding is the cardinal symptom of endometrial cancer. Occasionally, women with endometrial cancer who have no abnormal uterine bleeding present with abnormal findings on cervical cytology. Seventy-five to 90 percent of women with endometrial carcinoma present with abnormal uterine bleeding [1-3]. The majority of patients are diagnosed with disease confined to the uterus and have a greater than 90 percent five-year survival rate.

The clinical features, diagnosis, and screening of women for endometrial cancer will be reviewed here. An overview of endometrial cancer can be found separately (see "Overview of endometrial carcinoma"). Related topics are discussed in detail separately, including:

Histopathology and pathogenesis (See "Endometrial carcinoma: Histopathology and pathogenesis".)

Epidemiology and risk factors (See "Endometrial carcinoma: Epidemiology and risk factors".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jun 6, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106:413.
  2. Kimura T, Kamiura S, Yamamoto T, et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004; 85:145.
  3. Seebacher V, Schmid M, Polterauer S, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 2009; 9:460.
  4. Espindola D, Kennedy KA, Fischer EG. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clin North Am 2007; 34:717.
  5. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004; 59:368.
  6. Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.
  7. http://seer.cancer.gov/statfacts/html/corp.html (Accessed on June 06, 2016).
  8. Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200:678.e1.
  9. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012; 120:197.
  10. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11:201.
  11. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007; 105:801.
  12. Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012; 120:998.
  13. Twu NF, Chen SS. Five-year follow-up of patients with recurrent postmenopausal bleeding. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:628.
  14. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995; 86:38.
  15. Frumovitz M, Singh DK, Meyer L, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95:463.
  16. Guidos BJ, Selvaggi SM. Detection of endometrial adenocarcinoma with the ThinPrep Pap test. Diagn Cytopathol 2000; 23:260.
  17. Schorge JO, Hossein Saboorian M, Hynan L, Ashfaq R. ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer 2002; 96:338.
  18. Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol 2001; 45:555.
  19. Dash RC, Doud LG. Correlation of pap smear abnormalities in endometrial adenocarcinomas (Abstract). Acta Cytol 2001; 45:835.
  20. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010; 139:1927.
  21. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6.
  22. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.
  23. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400.
  24. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Accessed on January 18, 2012).